Map Pharma (MAPP) Hosting Call to Discuss Levadex: Doesn't Expect to Change Device Amid CRL, to Submit Request for FDA Meeting Today

Article Stock Quotes (2) Comments (0)

Map Pharma (Nasdaq: MAPP) is currently hosting an investor call related to Levadex. Below are some highlights.

• The FDA did not request more clinical studies and instead is concerned with third-party manufacturing.
  
• The FDA also had questions about the usability of the inhaler.
  
• The Administration asked for more time to review data.
  
• MAP's CEO Tim Nelson said he doesn't expect any need for a change to the device.
  
• The company will submit a request for an FDA meeting today.
  
• An FDA meeting with the company may be 60-75 days away.
  
• Issues with the FDA have no effect on the company's contract with Allergan (NYSE: AGN).

Shares of MAP Pharma last traded at $14 even, down more than 18 percent from Monday's close.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
• Sciclone (SCLN) Enters Licensing Agreement with Neucardin in East Asia
• Oramed Pharma (ORMP) OK'd by FDA for ORMD-0801 IND

Create E-mail Alert Related Categories

Conference Calls, Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?